Exact Sciences Approves Abbott Merger While Rejecting Executive Compensation Plan
Exact Sciences stockholders at a special meeting on Feb. 23 approved the proposed merger with Abbott to integrate its cancer-screening tests into Abbott’s diagnostics division. Shareholders simultaneously rejected the board’s executive compensation proposal, forcing management to revise its pay package.
1. Merger Approval at Special Meeting
On Feb. 23, Exact Sciences held a special shareholder meeting where a majority approved the merger agreement with Abbott laboratories. The vote clears the path for Exact’s cancer-screening tests to be integrated into Abbott’s existing diagnostics business.
2. Executive Compensation Proposal Fails
At the same meeting, shareholders voted down the board’s proposed executive compensation plan, indicating investor dissatisfaction with the current pay structure. The failure means the board must return with a revised package that meets shareholder expectations.
3. Implications and Next Steps
With merger approval secured, parties will move forward with regulatory filings and customary closing conditions ahead of the expected integration timeline. Concurrently, management will engage with major investors to develop a new executive pay proposal for a future vote.